Why is 'this deal is accretive' not the same statement as 'this is a good deal'? Give a one-sentence explanation an MD would accept.

What interviewers are really testing

Accretion/dilution intuition questions are a fixture at every level of IB and M&A interviewing because they test whether a candidate has internalized why a deal moves EPS, not just whether they can crank a formula. Interviewers will often ask the intuition version first ("if Company A buys Company B, when is that accretive?") with no numbers at all, specifically to see if you reach for the earnings-yield framing before reaching for a spreadsheet.

First, can you explain accretion/dilution without a single number? "The acquirer is buying a stream of earnings; if that stream costs less than the acquirer's cost of the money used to buy it, EPS goes up" is the sentence a strong candidate says in the first five seconds.

Second, do you know the P/E shortcut, and its limits? Many candidates memorize "higher P/E buying lower P/E is accretive" without knowing this only holds for all-stock deals with no synergies. Interviewers will deliberately ask a cash or debt-financed version next to see if you reach for the same (wrong) shortcut or correctly pivot to comparing earnings yield against after-tax financing cost.

Third, do you separate accretion from value creation unprompted? The strongest candidates volunteer, without being asked, that an accretive deal is not necessarily a good deal, and a dilutive deal is not necessarily a bad one. At elite boutiques (Evercore, PJT, Lazard, Qatalyst, Perella Weinberg), where the work is fundamentally about advising on value, not just executing models, this judgment point is often weighted as heavily as the mechanics.

Fourth, can you reason directionally under time pressure? A common superday move is a rapid-fire chain: "Is this deal more or less accretive if the acquirer pays a lower premium? If rates rise? If it uses more stock instead of cash?" Strong candidates answer each in one sentence using the earnings-yield-versus-cost-of-financing lens, without re-deriving the whole formula each time.

Signal mastery by leading with the framework, not the formula: "Two things move: the earnings you're buying and the cost of the money you used to buy them. Let me frame which way each pulls before I compute anything."

Common traps

Trap 1: Treating "accretive" as synonymous with "good deal." This is the single most common and most damaging mistake. Accretion is a financing/accounting artifact of year-one EPS; it says nothing about whether the price paid is justified by the value received.

Say it out loud: "Accretion tells me the deal is mechanically accretive to EPS: it doesn't tell me whether we overpaid. I'd want to see the premium paid against the present value of synergies before calling this a good deal."

Trap 2: Applying the P/E shortcut to a cash or debt-financed deal. "Acquirer P/E above target P/E means accretive" is only true for all-stock consideration. In a cash or debt deal, you must compare the target's earnings yield at the price paid against the after-tax cost of financing, not the acquirer's own trading multiple.

Say it out loud: "The P/E rule only holds when the deal is 100% stock. For a cash or debt deal, I compare the target's earnings yield to the after-tax cost of the cash or debt used, not to the acquirer's own multiple."

Trap 3: Ignoring that the earnings yield must be computed on the price actually paid, including the premium, not the target's unaffected trading price. A target may look cheap at its pre-deal share price but expensive once a 30% control premium is added.

Say it out loud: "I need the earnings yield on the offer price, not the pre-announcement price: the premium is real money the acquirer is paying, so it belongs in the denominator."

Trap 4: Forgetting that only stock consideration changes the share count. Candidates sometimes assume any large deal dilutes EPS through share issuance, even when the deal is entirely cash- or debt-funded.

Say it out loud: "Cash and debt deals don't add a single new share: dilution or accretion in that case comes entirely from the income statement, through financing costs versus earnings added, not from a bigger share count."

Trap 5: Assuming higher growth or strategic rationale automatically shows up in year-one accretion. A fast-growing target's earnings power may be years away; year-one accretion math only reflects today's net income, not the future growth an acquirer is actually buying.

Say it out loud: "Year-one accretion is a snapshot of current earnings, not a reflection of the growth thesis; a strategically compelling, high-growth target can easily be dilutive in year one and still be the right deal."